Controlled release arginine alpha ketoglutarate
View Patent ↗An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.
1. A controlled release oral dosage formulation, comprising:
about 50-70% arginine α-ketoglutarate; and
an excipient material comprising the remainder of the formulation;
wherein excipient is chosen from microcrystalline cellulose, hydroxypropylmethyl cellulose, ethylcellulose, cellulose acetate butyrate, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyethylene oxide, polyvinylpyrrolidone, polyethylene glycol, zein, poly-DL-lactide-co-glycolide, dicalcium phosphate, calcium sulfate, and mixture thereof;
wherein the formulation is characterized by releasing the arginine α-ketoglutarate in a manner so as to increase a period of time over which a therapeutic level of arginine α-ketoglutarate is maintained as compared to a quick release formulation.
2. The formulation of claim 1 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for a period of time which is 10% or more longer as compared to a quick release formulation.
3. The formulation of claim 1 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for a period of time which is 50% or more longer as compared to a quick release formulation.
4. The formulation of claim 1 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for a period of time which is 100% or more longer as compared to a quick release formulation.
5. The formulation of claim 1 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for a period of time which is 200% or more longer as compared to a quick release formulation.
6. The formulation of claim 1 , wherein the releasing is sufficiently slow that a maximum level of arginine α-ketoglutarate obtained is less as compared to a maximum level obtained with a quick release formulation.
7. The formulation of claim 1 , wherein the releasing is sufficiently slow that a maximum level of arginine α-ketoglutarate obtained is 50% or more, less as compared to a maximum level obtained with a quick release formulation.
8. The formulation of claim 1 , wherein the releasing of arginine α-ketoglutarate is at a rate of about 25% or less per hour after an initial release rate within 30 minutes following administration as compared to a quick release formulation.
9. The formulation of claim 1 , wherein the releasing of arginine α-ketoglutarate is at a rate of about 50% or less per hour after an initial release rate within 30 minutes following administration as compared to a quick release formulation.
10. A method of treating atherosclerosis in a human patient, comprising:
administering to a human patient a controlled release formulation of arginine α-ketoglutarate which formulation is characterized by maintaining a therapeutic level of arginine α-ketoglutarate in the patient's circulatory system over a period of time greater than that obtained with a quick release formulation; and
repeating the administering on three or more consecutive days thereby maintaining a therapeutic level of arginine α-ketoglutarate in the patient's circulatory system over a therapeutically effective period of time on three or more consecutive days.
11. The method of claim 10 , wherein the therapeutic level is maintained over a period of time which is 10% or more than that obtained with a quick release formulation and further wherein the repeating is over thirty or more consecutive days.
12. The method of claim 10 , wherein the therapeutic level is maintained over a period of time which is 100% or more than that obtained with a quick release formulation and further wherein the repeating is over thirty or more consecutive days.
13. The method of claim 12 , wherein the therapeutic level is a level sufficient to obtain measurable increase in prolyl hydroxylase and lysyl hydroxylase activity in a human patient.
14. The method of claim 12 , wherein the therapeutic level is a level sufficient to prevent protein glycation associated with atheroslerosis, cataract formation and retinopathy.